# Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

> **NCT00000773** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (—)

## Conditions studied

- Pneumonia, Pneumocystis Carinii
- HIV Infections

## Interventions

- **DRUG:** Atovaquone

## Key facts

- **NCT ID:** NCT00000773
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1996-09
- **Target enrollment:** 24 (—)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000773, "Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*